January 9, 2024 C-Path Appoints Dr. Klaus Romero as New CEO Longtime quantitative medicine and regulatory science expert to spearhead C-Path's collaborative efforts in accelerating...
December 12, 2023 C-Path Welcomes Mucopolysaccharidosis Clinical Trial Data Contribution from Children’s Hospital of Orange County into RDCA-DAP TUCSON, Ariz., December 12, 2023 – C-Path (Critical Path Institute) is thrilled to announce a significant addition to its Rare D
December 12, 2023 C-Path’s RDCA-DAP Program and PicnicHealth Announce Data Collaboration to Accelerate Rare Disease Research TUCSON, Ariz., December 12, 2023 – Critical Path Institute (C-Path), a leader in advancing rare disease research, is pleased to
July 18, 2023 C-Path Integrates European Offices to Optimize Global Operations and Collaborative Partnerships AMSTERDAM and TUCSON, Ariz., July 18, 2023 — Critical Path Institute (C-Path) announced today the completion of the integration
July 13, 2023 C-Path and Vivpro Formalize Partnership to Accelerate Drug Development The strategic collaboration between C-Path and Vivpro seeks to leverage Vivpro’s innovative biointelligence platform, foster
May 31, 2023 C-Path’s Transplant Therapeutics Consortium’s Work Highlighted in Recent Publication in the American Journal of Transplantation C-Path’s Transplant Therapeutics Consortium is pleased to announce the recent publication in the American Journal of Transplan
March 14, 2023 C-Path Welcomes BioCentury Inc. Co-Founder Bernstein to Board of Directors Dr. Bernstein will help steer the strategic vision of C-Path as the organization’s newest board member TUCSON, Ariz., March 14,
January 25, 2023 C-Path Receives Letter of Support from EMA on Duchenne Muscular Dystrophy Clinical Trial Simulation Platform TUCSON, Ariz., Jan. 25, 2023 — Critical Path Institute (C-Path) today announced that the European Medicines Agency (EMA) has iss
April 2, 2014 Critical Path Institute Receives Grant to Accelerate Development of Tuberculosis Treatments
